Tue, Nov 26, 2024
Volume 13, Issue 1 (Jan-Feb 2019)
mljgoums 2019, 13(1): 6-11 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Soleimani S, Kamalzadeh M, Lotfi M. Preparation and Characterization of a Neutralizing Monoclonal Antibody against Poliovirus Type 1 (Mahoney Strain). mljgoums 2019; 13 (1) :6-11
URL: http://mlj.goums.ac.ir/article-1-1146-en.html
URL: http://mlj.goums.ac.ir/article-1-1146-en.html
1- Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975-148, Karaj, Iran , sina.soleimani@gmail.com
2- Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975-148, Karaj, Iran
2- Razi Vaccine & Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), P.O. Box 31975-148, Karaj, Iran
Abstract: (6376 Views)
ABSTRACT
Background and Objectives: Poliomyelitis remains a major public health problem in developing countries, which signify the need for extensive diagnostic and prevention research. The aim of the present study was to design monoclonal antibodies (MAbs) against poliovirus type I with biomedical, diagnostic and therapeutic applications.
Methods: B-cells were isolated from a mouse challenged with polio antigen injection. The B-cell were fused with myeloma tumor cells. After evaluation and screening of approximately 250 hybridoma colons by ELISA, 35 colons with the highest antibody titer and no cross-reactivity were selected and subsequently cloned by limiting dilution. Finally, three colons capable of secreting MAbs against epitopes of poliovirus type I were used for MAb production. Next, the MAbs were characterized by antibody assays, isotyping, epitope analysis (western blot), cross-reactivity test, stability test, sterility test and mycoplasma test.
Results: The results indicated that the MAbs were of IgG1 kappa chain, had good stability and no cross-reactivity. In western blot, a band at 26 kDa which is associated to VP3 neutralization protein was observed.
Conclusion: These serotype-specific MAbs can be potentially used for identification of type I poliovirus for research, diagnostic and prevention purposes.
Keywords: Monoclonal antibody, Hybridoma, Poliomyelitis, Poliovirus.
Background and Objectives: Poliomyelitis remains a major public health problem in developing countries, which signify the need for extensive diagnostic and prevention research. The aim of the present study was to design monoclonal antibodies (MAbs) against poliovirus type I with biomedical, diagnostic and therapeutic applications.
Methods: B-cells were isolated from a mouse challenged with polio antigen injection. The B-cell were fused with myeloma tumor cells. After evaluation and screening of approximately 250 hybridoma colons by ELISA, 35 colons with the highest antibody titer and no cross-reactivity were selected and subsequently cloned by limiting dilution. Finally, three colons capable of secreting MAbs against epitopes of poliovirus type I were used for MAb production. Next, the MAbs were characterized by antibody assays, isotyping, epitope analysis (western blot), cross-reactivity test, stability test, sterility test and mycoplasma test.
Results: The results indicated that the MAbs were of IgG1 kappa chain, had good stability and no cross-reactivity. In western blot, a band at 26 kDa which is associated to VP3 neutralization protein was observed.
Conclusion: These serotype-specific MAbs can be potentially used for identification of type I poliovirus for research, diagnostic and prevention purposes.
Keywords: Monoclonal antibody, Hybridoma, Poliomyelitis, Poliovirus.
Research Article: Original Paper |
Received: 2018/11/24 | Accepted: 2018/11/24 | Published: 2018/11/24 | ePublished: 2018/11/24
Received: 2018/11/24 | Accepted: 2018/11/24 | Published: 2018/11/24 | ePublished: 2018/11/24
References
1. Soleimani S BN. Stability Study of Razi Trivalent and Monovalent Oral Poliomyelitis Vaccine. Archives of Razi Institute. 2012; 67(1): 27-34. DOI: 10.22092/ari.2016.103884.
2. Soleimani S, Lotfi M, Taghavian M, Shahkarami M. Evaluation of Adventitious Agents in MMR & Oral Poliomyelitis Vaccines. Iran J Virol. 2011; 5(1): 15-22 [DOI:10.21859/isv.5.1.15]
3. De Jesus NH. Epidemics to eradication: the modern history of poliomyelitis. Virology journal. 2007; 4(1): 70. [DOI:10.1186/1743-422X-4-70]
4. Mateen FJ, Shinohara RT, Sutter RW. Oral and inactivated poliovirus vaccines in the newborn: a review. Vaccine. 2013; 31(21): 2517-24. doi: 10.1016/j.vaccine.2012.06.020. [DOI:10.1016/j.vaccine.2012.06.020]
5. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, et al. Review and assessment of poliovirus immunity and transmission: Synthesis of knowledge gaps and identification of research needs. Risk Analysis. 2013; 33(4): 606-46. doi: 10.1111/risa.12031. [DOI:10.1111/risa.12031]
6. Fields B, Knipe D, Howley P. Fields virology. 6th ed. Philadelphia, PA, USA. Lippincott Williams & Wilkins. 2013; 2456
7. Loyau J, Rousseau F. Cloning, reformatting, and small-scale expression of monoclonal antibody isolated from mouse, rat, or hamster hybridoma. Methods Mol Biol. 2014;1131:207-28. doi: 10.1007/978-1-62703-992-5_13. [DOI:10.1007/978-1-62703-992-5_13]
8. Nissim A, Chernajovsky Y. Historical development of monoclonal antibody therapeutics. Handb Exp Pharmacol. 2008; (181): 3-18. [DOI:10.1007/978-3-540-73259-4_1]
9. Jeong JS, Jiang L, Albino E, Marrero J, Rho HS, Hu J, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. 2012;11(6):O111.016253. doi: 10.1074/mcp.O111.016253. [DOI:10.1074/mcp.O111.016253]
10. Adams JJ, Nelson B, Sidhu SS. Recombinant genetic libraries and human monoclonal antibodies. Human monoclonal antibodies: Springer; 2014. p. 149-70.
11. Yu X, McGraw PA, House FS, Crowe Jr JE. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. Journal of immunological methods. 2008;336(2):142-51. [DOI:10.1016/j.jim.2008.04.008]
12. Freshney RI. Cryopreservation. Culture of Animal Cells. 2010.
13. Nelson P, Reynolds G, Waldron E, Ward E, Giannopoulos K, Murray P. Demystified…: monoclonal antibodies. Molecular pathology. 2000;53(3):111. [DOI:10.1136/mp.53.3.111]
14. Eswaran SP, Praharaj A, Chander Y, Nagendra A. Potency titration of oral polio vaccine by estimation of live virus content using tissue culture technique. Medical Journal Armed Forces India. 2003;59(2):105-7. [DOI:10.1016/S0377-1237(03)80049-7]
15. Apostol LN, Suzuki A, Bautista A, Galang H, Paladin FJ, Fuji N, et al. Detection of non‐polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines. Journal of medical virology. 2012;84(4):624-31. [DOI:10.1002/jmv.23242]
16. Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy. 2011;3(3):371-80. [DOI:10.2217/imt.11.4]
17. Yang J, Shen MH. Polyethylene glycol-mediated cell fusion. Methods Mol Biol. 2006; 325: 59-66.
18. Kim H-Y, Stojadinovic A, Izadjoo MJ. Immunization, hybridoma generation, and selection for monoclonal antibody production. Methods Mol Biol. 2014; 1131: 33-45. doi: 10.1007/978-1-62703-992-5_3. [DOI:10.1007/978-1-62703-992-5_3]
19. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005; 59: 587-635. DOI:10.1146/annurev.micro.58.030603.123625. [DOI:10.1146/annurev.micro.58.030603.123625]
20. Soleimani S, Abedi Kiasari B. Evaluation and comparison of Hela, Hep2C and Vero cell lines sensitivity to polio vaccinal virus using micro and macro vaccine potency tests. Archives of Razi Institute. 2012; 67(2): 125-131. DOI: 10.22092/ari.2016.103896.
21. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nature biotechnology. 2005; 23(9): 1073-8. DOI:10.1038/nbt0905-1073. [DOI:10.1038/nbt0905-1073]
22. Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Antibody methods and protocols: Springer. 2012; 911: 117-35. doi: 10.1007/978-1-61779-931-0_7. [DOI:10.1007/978-1-61779-931-0_7]
23. Puligedda RD, Kouiavskaia D, Adekar SP, Sharma R, Kattala CD, Rezapkin G, et al. Human monoclonal antibodies that neutralize vaccine and wild-type poliovirus strains. Antiviral research. 2014;108: 36-43. doi: 10.1016/j.antiviral.2014.05.005. [DOI:10.1016/j.antiviral.2014.05.005]
24. Bradbury A, Pluckthun A. Standardize antibodies used in research: to save millions of dollars and dramatically improve reproducibility, protein-binding reagents must be defined by their sequences and produced as recombinant proteins, say Andrew Bradbury, Andreas Pluckthun and 110 co-signatories. Nature. 2015; 518(7537): 27-30. [DOI:10.1038/518027a]
25. Kouiavskaia D, Chen Z, Dragunsky E, Mirochnitchenko O, Purcell R, Chumakov K. A single chimpanzee-human neutralizing monoclonal antibody provides post-exposure protection against type 1 and type 2 polioviruses. J Clin Virol. 2015; 65: 32-7. doi: 10.1016/j.jcv.2015.01.023. [DOI:10.1016/j.jcv.2015.01.023]
26. Gupta C, Sokhey J, Gupta R, Singh H. Development of allogenic hybridomas for production of monoclonal antibodies against oral polio vaccine strains. Vaccine. 1991; 9(11): 853-4. [DOI:10.1016/0264-410X(91)90233-V]
27. Horie H, Sato M, Doi Y, Hashizume S. The use of antipoliovirus monoclonal antibodies as an improved safety test for oral live poliomyelitis vaccine. Vaccine. 1996; 14(1): 35-41. [DOI:10.1016/0264-410X(95)00159-X]
28. Gary Jr HE, Freeman C, Pe-aranda S, Maher K, Anderson L, Pallansch MA. Comparison of a monoclonal antibody-based IgM capture ELISA with a neutralization assay for assessing response to trivalent oral poliovirus vaccine. J Infect Dis. 1997; 175(Supplement_1): S264-S7.
29. Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Current pharmaceutical biotechnology. 2008; 9(6): 468-81. [DOI:10.2174/138920108786786402]
30. Hashido M, Horie H, Abe S, Hashizume S, Agboatwalla M, Isomura S, et al. Evaluation of an Enzyme‐Linked Immunosorbent Assay Based on Binding Inhibition for Type‐Specific Quantification of Poliovirus Neutralization‐Relevant Antibodies. Microbiology and immunology. 1999; 43(1): 73-7. [DOI:10.1111/j.1348-0421.1999.tb02375.x]
31. Chen Z, Fischer ER, Kouiavskaia D, Hansen BT, Ludtke SJ, Bidzhieva B, et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proceedings of the National Academy of Sciences. 2013; 110(50): 20242-7. [DOI:10.1073/pnas.1320041110]
32. He Y, Mueller S, Chipman PR, Bator CM, Peng X, Bowman VD, et al. Complexes of poliovirus serotypes with their common cellular receptor, CD155. Journal of virology. 2003; 77(8): 4827-35. [DOI:10.1128/JVI.77.8.4827-4835.2003]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.